Green Alpha Advisors LLC Acquires New Shares in Personalis, Inc. $PSNL

Green Alpha Advisors LLC acquired a new position in shares of Personalis, Inc. (NASDAQ:PSNL) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 67,467 shares of the company’s stock, valued at approximately $904,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Caitong International Asset Management Co. Ltd raised its position in Personalis by 76.1% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock valued at $27,000 after purchasing an additional 1,479 shares during the last quarter. Legal & General Group Plc acquired a new stake in shares of Personalis during the second quarter valued at about $30,000. International Assets Investment Management LLC acquired a new stake in shares of Personalis during the fourth quarter valued at about $31,000. BNP Paribas Financial Markets grew its holdings in shares of Personalis by 406.4% during the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after purchasing an additional 5,177 shares during the last quarter. Finally, Focus Partners Wealth bought a new stake in shares of Personalis during the first quarter worth about $47,000. Institutional investors and hedge funds own 61.91% of the company’s stock.

Personalis Stock Up 8.9%

Shares of NASDAQ PSNL opened at $18.38 on Friday. The company has a market capitalization of $1.92 billion, a PE ratio of -16.86 and a beta of 2.27. The firm has a fifty day simple moving average of $13.30 and a 200 day simple moving average of $9.68. Personalis, Inc. has a twelve month low of $4.65 and a twelve month high of $18.89.

Personalis (NASDAQ:PSNL) last announced its earnings results on Tuesday, August 4th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.04). Personalis had a negative net margin of 153.84% and a negative return on equity of 46.47%. The business had revenue of $22.36 million for the quarter, compared to the consensus estimate of $16.69 million. As a group, equities analysts expect that Personalis, Inc. will post -1.07 earnings per share for the current fiscal year.

Analysts Set New Price Targets

PSNL has been the subject of several recent research reports. TD Cowen reaffirmed a “buy” rating on shares of Personalis in a research note on Wednesday, July 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a research report on Friday, July 17th. BTIG Research boosted their target price on shares of Personalis from $11.00 to $16.25 and gave the stock a “buy” rating in a report on Monday, July 20th. Lake Street Capital cut shares of Personalis from a “buy” rating to a “hold” rating and set a $16.25 price target for the company. in a research report on Monday, July 20th. Finally, Zacks Research downgraded shares of Personalis from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 21st. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $14.25.

Insider Activity

In related news, CFO Aaron Tachibana sold 51,251 shares of the stock in a transaction on Friday, June 26th. The stock was sold at an average price of $13.18, for a total value of $675,488.18. Following the transaction, the chief financial officer directly owned 198,833 shares in the company, valued at $2,620,618.94. This trade represents a 20.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher M. Hall sold 100,000 shares of the firm’s stock in a transaction on Friday, June 26th. The shares were sold at an average price of $13.15, for a total transaction of $1,315,000.00. Following the completion of the transaction, the chief executive officer directly owned 235,986 shares in the company, valued at $3,103,215.90. This trade represents a 29.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 435,032 shares of company stock worth $5,599,929 in the last quarter. Company insiders own 4.20% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.